CN107367569A - A kind of detection method of butyrate clevidipine about material - Google Patents
A kind of detection method of butyrate clevidipine about material Download PDFInfo
- Publication number
- CN107367569A CN107367569A CN201610319340.XA CN201610319340A CN107367569A CN 107367569 A CN107367569 A CN 107367569A CN 201610319340 A CN201610319340 A CN 201610319340A CN 107367569 A CN107367569 A CN 107367569A
- Authority
- CN
- China
- Prior art keywords
- detection method
- ethanol
- water
- methanol
- butyrate clevidipine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/89—Inverse chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/062—Preparation extracting sample from raw material
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The present invention provides a kind of detection method of butyrate clevidipine, and this method uses reversed phase liquid chromatography, and optimum chromatogram condition is as follows：Chromatographic column is Welchrom C18 chromatographic columns；Flowing phase composition is methanol: ethanol: water=15~20: 40~45: 37~42 or acetonitrile: ethanol: water=16: 40: 44；Flow rate of mobile phase is 1.0ml/min；Detection wavelength is 240nm；Column temperature is 40 DEG C；Detector is UV-detector or PDAD.Detection method provided by the invention has higher sensitivity and specificity, it is simple to operation, separating degree meets the requirements, the plurality of impurities content in butyrate clevidipine can rapidly and accurately be detected, it can be used for the quality control of butyrate clevidipine, the synthesis tool to antihypertensive butyrate clevidipine is of great significance.
Description
Technical field
The invention belongs to Pharmaceutical Analysis technical field, more particularly to a kind of detection side of the butyrate clevidipine about material
Method.
Background technology
Chemical entitled 4- (2', 3'- the dichlorophenyl) -1,4- two of butyrate clevidipine (Clevidipine butyrate)
Hydrogen -2,6- dimethyl-3,5-dipicolinic acid (butyryl acyloxy methyl) (methyl) ester, outward appearance are white crystalline powder, molecule
Formula is C21H23Cl2NO6, molecular weight 456.32, CAS accession number is 167221-71-8.The chemical structural formula of butyrate clevidipine
It is as follows：
Butyrate clevidipine is a kind of injection-type drug for hypertension, for treating acute hypertension, effect sustainable 72
Hour, the medicine can or patient invalid in oral drugs use when being inconvenient to use oral drugs, work rapidly.With existing high blood
Pressing thing is different by kidney or liver metabolism, and butyrate clevidipine is metabolized, will not put aside in vivo in blood, especially suitable for
The patient of those late period organ injuries.
Because butyrate clevidipine and its impurity difference are smaller, the method separating effect of in general reversed-phase liquid chromatography compared with
Difference, it is therefore desirable to develop a kind of method that impurity to butyrate clevidipine carries out effective detection.
The content of the invention
It is an object of the invention to provide a kind of detection method of butyrate clevidipine about material, and the detection method is using anti-
Mutually high phase liquid chromatography, its chromatographic condition are as follows：
Chromatographic column：Octadecylsilane chemically bonded silica post；
The composition of mobile phase is calculated as methanol by volume: ethanol: water=15~20: 40~45: 37~42 or be acetonitrile:
Ethanol: water=16: 40: 44；
Detector：UV-detector or PDAD；
The method according to the invention, wherein, the composition of the mobile phase is calculated as methanol by volume: ethanol: water=15: 45
: 40, methanol: ethanol: water=18: 42: 40, methanol: ethanol: water=18: 40: 42, methanol: ethanol: water=19: 44: 37, methanol
: ethanol: water=20: 40: 40.
The method according to the invention, wherein, the flow rate of mobile phase is 0.8~1.5ml/min, preferably 0.8~
1.2ml/min, more preferably 1.0ml/min.
The method according to the invention, wherein, the Detection wavelength in the chromatographic condition is 220~250nm, is preferably
240nm。
The method according to the invention, wherein, column temperature is 30~50 DEG C, preferably 40 DEG C in the chromatographic condition.
The method according to the invention, wherein, the octadecylsilane chemically bonded silica post is Welchrom C18 chromatographic columns.
The method according to the invention, wherein, the solvent for dissolving test sample is methanol, acetonitrile or mobile phase, is preferably flowed
Phase.
The method according to the invention, wherein, in the detection method, need testing solution concentration is 0.2~1.0mg/ml,
Preferably 0.5mg/ml；The single needle sample size of need testing solution is 1~40 μ l, preferably 20 μ l.
Detection method of the butyrate clevidipine provided by the invention about material realizes butyrate clevidipine and its 15
The separation of impurity and 3 intermediates, there is higher sensitivity and specificity, separating degree meets States Pharmacopoeia specifications, available for butyric acid
The quality control of clevidipine, has important practical significance.The mobile phase of the method for the present invention is methanol, second alcohol and water or second
The mixed solution of three kinds of nitrile, second alcohol and water solvents, common C18 posts are not used to the requirement of additive and pH value, chromatographic column,
Method is simple, workable.
Brief description of the drawings
Hereinafter, embodiment of the present invention is described in detail with reference to accompanying drawing, wherein：
Fig. 1 is the according to an embodiment of the invention 2 obtained liquid chromatogram of detection method；
Fig. 2 is the according to an embodiment of the invention 3 obtained liquid chromatogram of detection method；
Fig. 3 is the according to an embodiment of the invention 4 obtained liquid chromatogram of detection method；
Fig. 4 is the according to an embodiment of the invention 5 obtained liquid chromatogram of detection method；
Fig. 5 is the according to an embodiment of the invention 6 obtained liquid chromatogram of detection method；
Fig. 6 is the according to an embodiment of the invention 7 obtained liquid chromatogram of detection method；
Fig. 7 is the according to an embodiment of the invention 8 obtained liquid chromatogram of detection method；
Fig. 8 is the according to an embodiment of the invention 9 obtained liquid chromatogram of detection method；
Fig. 9 is the according to an embodiment of the invention 10 obtained liquid chromatogram of detection method.
Embodiment
The present invention is further illustrated below by specific embodiment, it should be understood, however, that, these embodiments are only
It is used for illustrating in more detail, and is not to be construed as limiting in any manner the present invention.
When butyrate clevidipine impurity and the numbering of intermediate, chemical constitution and appearance that the detection method of the present invention is related to
Between referring to table 1.
Embodiment 1
The selection of sample dissolution solvent and concentration
Selected for the solvent of sample dissolution, respectively with acetonitrile, methanol, mobile phase sample dissolution, they can dissolve.
In order to reduce the appearance of solvent peak, mobile phase sample dissolution is used.
During using mobile phase as the solvent of sample, mobile phase is made into 0.2mg/ml, 0.5mg/ml and 1.0mg/ respectively
Tri- kinds of concentration of ml.Although these three concentration can realize the separation of impurity, due to using 0.2mg/ml when, the response of detection
Value is too small, and when using 1.0mg/ml, and flowing phase concentration is unfavorable for greatly very much the separation of sample, and final choice 0.5mg/ml is as supplying
The concentration of test sample solution.
Embodiment 2
Using the high performance liquid chromatographs of U.S. Agilent 1260, automatic sampler；Welchrom C18 posts；Mobile phase body
Product ratio is acetonitrile: ethanol: water=16: 40: 44；Sample size is 20 μ l；Detection wavelength is 240nm；Flow velocity is 1.0ml/min；Post
Temperature is 35 DEG C.
Experimental procedure：
Take butyrate clevidipine and its impurity I, III, IV, V appropriate, every 1ml is made and is contained with flowing phased soln and dilution
Butyrate clevidipine 0.50mg, the μ g of impurity 0.5 solution, shake up, as need testing solution.Determined by above-mentioned condition sample introduction, note
Chromatogram is recorded, as a result sees Fig. 1.Fig. 1 shows that separating degree meets the requirements between butyrate clevidipine and its impurity and impurity and impurity.
Embodiment 3
Using the high performance liquid chromatographs of U.S. Agilent 1260, automatic sampler；WelchromC18 posts (4.6 ×
250mm,5μm)；Mobile phase is methanol: ethanol: water=15: 45: 40；Sample size is 20 μ l；Detection wavelength is 240nm；Flow velocity is
1.0ml/min；Column temperature is 40 DEG C.
Experimental procedure：
Take butyrate clevidipine and its impurity I, III, IV, V appropriate, every 1ml is made and is contained with flowing phased soln and dilution
Butyrate clevidipine 0.50mg, the μ g of impurity 0.5 solution, shake up, as need testing solution.Determined by above-mentioned condition sample introduction, note
Chromatogram is recorded, as a result sees Fig. 2.Fig. 2 shows that separating degree meets the requirements between butyrate clevidipine and its impurity and impurity and impurity
Embodiment 4
Using the high performance liquid chromatographs of U.S. Agilent 1260, automatic sampler；Welchrom C18 posts (4.6 ×
250mm,5μm)；Mobile phase is methanol: ethanol: water=18: 42: 40；Sample size is 20 μ l；Detection wavelength is 240nm；Flow velocity is
1.0ml/min；Column temperature is 40 DEG C.
Experimental procedure
Take butyrate clevidipine and its impurity I, III, IV, V appropriate, every 1ml is made and is contained with flowing phased soln and dilution
Butyrate clevidipine 0.50mg, the μ g of impurity 0.5 solution, shake up, and are determined as need testing solution by above-mentioned condition sample introduction, record
Chromatogram, as a result see Fig. 3.Fig. 3 shows that separating degree is preferable between butyrate clevidipine and its impurity and impurity and impurity, minimum point
Meet States Pharmacopoeia specifications from degree.
Embodiment 5
The high performance liquid chromatographs of U.S. Agilent 1260, automatic sampler；Waters C18 posts (4.6 × 250mm, 5 μ
m)；Mobile phase is methanol: ethanol: water=20: 45: 35；Sample size is 20 μ l；Detection wavelength is 240nm；Flow velocity is 1.0ml/
min；Column temperature is 30 DEG C.
Experimental procedure：
Take butyrate clevidipine and its impurity I, II, III, IV, V, VI, VII appropriate, be made of flowing phased soln and dilution
Contain butyrate clevidipine 0.50mg, the μ g of impurity 0.5 solution per 1ml, shake up, as need testing solution.Enter by above-mentioned condition
Sample determines, and records chromatogram, as a result sees Fig. 4.Fig. 4 shows that butyrate clevidipine impurity II does not separate with impurity V.
Embodiment 6
Using the high performance liquid chromatographs of U.S. Agilent 1260, automatic sampler；Welchrom C18 posts (4.6 ×
250mm,5μm)；Mobile phase is acetonitrile: ethanol: water=30: 50: 20；Sample size is 20 μ l；Detection wavelength is 240nm；Flow velocity is
1.0ml/min；Column temperature is 50 DEG C.
Experimental procedure：
Butyrate clevidipine and its appropriate impurity are taken, every 1ml, which is made, with flowing phased soln and dilution contains butyric acid chlorine dimension ground
Flat 0.50mg, the μ g of impurity 0.5 solution, shake up, as need testing solution.Determined by above-mentioned condition sample introduction, record chromatogram, knot
Fruit sees Fig. 5.Fig. 5 shows that butyrate clevidipine impurity V does not separate with principal component.
Embodiment 7
Using the high performance liquid chromatographs of U.S. Agilent 1260, automatic sampler；Welchrom C18 posts (4.6 ×
250mm,5μm)；Mobile phase is methanol: ethanol: water=30: 40: 30；Sample size is 20 μ l；Detection wavelength is 240nm；Flow velocity is
1.0ml/min；Column temperature is 40 DEG C.
Experimental procedure：
Take butyrate clevidipine and its impurity I, II, III, IV, V, VI, VII appropriate, be made of flowing phased soln and dilution
Contain butyrate clevidipine 0.50mg, the μ g of impurity 0.5 solution per 1ml, shake up, as need testing solution.Enter by above-mentioned condition
Sample determines, and records chromatogram, as a result sees Fig. 6.Fig. 6 shows that butyrate clevidipine impurity II, V does not separate with principal component.
Embodiment 8
Using the high performance liquid chromatographs of U.S. Agilent 1260, automatic sampler；WelchromC18 posts (4.6 ×
250mm,5μm)；Mobile phase is methanol: ethanol: water=20: 40: 40；Sample size is 20 μ l；Detection wavelength is 240nm；Flow velocity is
1.0ml/min；Column temperature is 40 DEG C.
Experimental procedure：
Take butyrate clevidipine and its impurity I, II, III, IV, V, VI, VII, VIII, Ⅸ, Ⅹ, Ⅺ, Ⅻ, Ⅹ III, Ⅹ IV, Ⅹ
Vth, intermediate I, intermediate II, intermediate III are appropriate, and every 1ml is made and is contained butyrate clevidipine with flowing phased soln and dilution
0.50mg, the μ g of impurity 0.5 solution, shake up, as need testing solution.Determined by above-mentioned condition sample introduction, record chromatogram, as a result
See Fig. 7.Fig. 7 shows that butyrate clevidipine impurity separates preferably with main peak.
Embodiment 9
Using the high performance liquid chromatographs of U.S. Agilent 1260, automatic sampler；WelchromC18 posts (4.6 ×
250mm,5μm)；Mobile phase is methanol: ethanol: water=18: 40: 42；Sample size is 20 μ l；Detection wavelength is 240nm；Flow velocity is
1.0ml/min；Column temperature is 40 DEG C.
Experimental procedure：
Take butyrate clevidipine and its impurity I, II, III, IV, V, VI, VII, VIII, Ⅸ, Ⅹ, Ⅺ, Ⅻ, Ⅹ III, Ⅹ IV, Ⅹ
Vth, intermediate I, intermediate II, intermediate III are appropriate, and every 1ml is made and is contained butyrate clevidipine with flowing phased soln and dilution
0.50mg, the μ g of impurity 0.5 solution, shake up, as need testing solution.By above-mentioned condition sample introduction determine, the results showed that impurity with
Main peak separating degree is good, meets the requirements.
Embodiment 10
Using the high performance liquid chromatographs of U.S. Agilent 1260, automatic sampler；WelchromC18 posts (4.6 ×
250mm,5μm)；Mobile phase is methanol: ethanol: water=19: 44: 37；Sample size is 20 μ l；Detection wavelength is 240nm；Flow velocity is
1.0ml/min；Column temperature is 40 DEG C.
Experimental procedure：
Take butyrate clevidipine and its impurity I, II, III, IV, V, VI, VII, VIII, Ⅸ, Ⅹ, Ⅺ, Ⅻ, Ⅹ III, Ⅹ IV, Ⅹ
Vth, intermediate I, intermediate II, intermediate III are appropriate, and every 1ml is made and is contained butyrate clevidipine with flowing phased soln and dilution
0.50mg, the μ g of impurity 0.5 solution, shake up, as need testing solution.By above-mentioned condition sample introduction determine, the results showed that impurity with
Main peak separating degree is good, meets the requirements.
Information of the butyrate clevidipine of table 1 about material
Claims (8)
1. detection method of a kind of butyrate clevidipine about material, it is characterised in that the detection method is using reverse efficient liquid
Phase chromatography, its chromatographic condition are as follows：
Chromatographic column：Octadecylsilane chemically bonded silica post；
The composition of mobile phase is calculated as methanol by volume: ethanol：Water=15~20: 40~45: 37~42 or be acetonitrile: ethanol
: water=16: 40: 44；
Detector：UV-detector or PDAD.
2. detection method according to claim 1, it is characterised in that the composition of the mobile phase is calculated as methanol by volume
: ethanol: water=15: 45: 40, methanol: ethanol: water=18: 42: 40, methanol: ethanol: water=18: 40: 42, methanol: ethanol: water
=19: 44: 37, or methanol: ethanol: water=20: 40: 40.
3. detection method according to claim 1 or 2, it is characterised in that the flow rate of mobile phase in the chromatographic condition is
0.8~1.5ml/min, preferably 0.8~1.2ml/min, more preferably 1.0ml/min.
4. detection method according to claim 1 or 2, it is characterised in that the Detection wavelength in the chromatographic condition is 220
~250nm, preferably 240nm.
5. detection method according to claim 1, it is characterised in that the column temperature in the chromatographic condition is 30~50 DEG C,
Preferably 40 DEG C.
6. detection method according to claim 1 or 2, it is characterised in that the octadecylsilane chemically bonded silica post is
Welchrom C18 chromatographic columns.
7. detection method according to claim 1 or 2, it is characterised in that dissolve the solvent of test sample for methanol, acetonitrile,
Mobile phase, preferably mobile phase.
8. detection method according to claim 1 or 2, it is characterised in that need testing solution in the chromatographic condition
Concentration is 0.2~1.0mg/ml, preferably 0.5mg/ml；The single needle sample size of need testing solution is 1~40 μ l, preferably 20 μ
l。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610319340.XA CN107367569A (en) | 2016-05-13 | 2016-05-13 | A kind of detection method of butyrate clevidipine about material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610319340.XA CN107367569A (en) | 2016-05-13 | 2016-05-13 | A kind of detection method of butyrate clevidipine about material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107367569A true CN107367569A (en) | 2017-11-21 |
Family
ID=60304041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610319340.XA Pending CN107367569A (en) | 2016-05-13 | 2016-05-13 | A kind of detection method of butyrate clevidipine about material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107367569A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102432527A (en) * | 2011-11-04 | 2012-05-02 | 浙江九旭药业有限公司 | Method for preparing clevidipine butyrate |
| CN103134891A (en) * | 2011-11-30 | 2013-06-05 | 天津金耀集团有限公司 | Measuring method of content of butyric acid clevidipine butyrate and content of related substances |
| CN103420899A (en) * | 2012-05-25 | 2013-12-04 | 四川科伦药物研究有限公司 | Purification method of clevidipine butyrate |
| CN104597192A (en) * | 2014-12-31 | 2015-05-06 | 武汉科福新药有限责任公司 | Method for detecting clevidipine butyrate and related substances in preparations of clevidipine butyrate |
| CN105092769A (en) * | 2015-01-15 | 2015-11-25 | 上海馨平医药科技发展有限公司 | Method for simultaneously detecting clevidipine butyrate and related substances |
-
2016
- 2016-05-13 CN CN201610319340.XA patent/CN107367569A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102432527A (en) * | 2011-11-04 | 2012-05-02 | 浙江九旭药业有限公司 | Method for preparing clevidipine butyrate |
| CN103134891A (en) * | 2011-11-30 | 2013-06-05 | 天津金耀集团有限公司 | Measuring method of content of butyric acid clevidipine butyrate and content of related substances |
| CN103420899A (en) * | 2012-05-25 | 2013-12-04 | 四川科伦药物研究有限公司 | Purification method of clevidipine butyrate |
| CN104597192A (en) * | 2014-12-31 | 2015-05-06 | 武汉科福新药有限责任公司 | Method for detecting clevidipine butyrate and related substances in preparations of clevidipine butyrate |
| CN105092769A (en) * | 2015-01-15 | 2015-11-25 | 上海馨平医药科技发展有限公司 | Method for simultaneously detecting clevidipine butyrate and related substances |
Non-Patent Citations (2)
| Title |
|---|
| 袁慧雅等: "丁酸氯维地平及其有关物质的测定和处理前研究", 《沈阳药科大学学报》 * |
| 陈晓雨等: "反相高效液相色谱法测定丁酸氯维地平及有关物质", 《医药导报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Han et al. | Preparative separation of gambogic acid and its C-2 epimer using recycling high-speed counter-current chromatography | |
| Chèze et al. | Simultaneous analysis of six amphetamines and analogues in hair, blood and urine by LC-ESI-MS/MS: application to the determination of MDMA after low Ecstasy intake | |
| WO2019242212A1 (en) | Liquid chromatography method for detecting related substances in parecoxib sodium and synthetic intermediates thereof | |
| CN104422743B (en) | A kind of method for separating and detecting of anticoagulation medicine | |
| Ye et al. | Pharmacokinetics of nuciferine and N-nornuciferine, two major alkaloids from Nelumbo nucifera leaves, in rat plasma and the brain | |
| JP6364479B2 (en) | Method for preparing R-type resveratrol dimer | |
| Xu et al. | Separation of twelve posaconazole related stereoisomers by multiple heart-cutting chiral–chiral two-dimensional liquid chromatography | |
| Kyerematen et al. | Radiometric-high-performance liquid chromatographic assay for nicotine and twelve of its metabolites | |
| Hewala et al. | Enantioselective HPLC-DAD method for the determination of etodolac enantiomers in tablets, human plasma and application to comparative pharmacokinetic study of both enantiomers after a single oral dose to twelve healthy volunteers | |
| CN104133012A (en) | Method for determining asenapine maleate racemate by using HPLC | |
| Rosetti et al. | Simultaneous enantio-and diastereo-selective high-performance liquid chromatography separation of paroxetine on an immobilized amylose-based chiral stationary phase under green reversed-phase conditions | |
| CN104569255B (en) | A kind of HPLC measures the method for Suvorexant intermediate | |
| Kirkpatrick et al. | Enantiomeric impurity analysis using circular dichroism spectroscopy with United States Pharmacopeia liquid chromatographic methods | |
| CN107192766B (en) | Method for measuring suvorexant chiral isomer by using HPLC | |
| CN103760286A (en) | Method for measuring optical purity of solifenacin succinate intermediate by high-performance liquid chromatography | |
| CN107367569A (en) | A kind of detection method of butyrate clevidipine about material | |
| Zheng et al. | Development and validation of an UPLC-PDA method for the determination of corilagin in rat plasma and its application to pharmacokinetic study | |
| Upmanis et al. | Mechanistic insights in chiral recognition of μ-opioid receptor agonist tetrapeptide on crown ether chiral stationary phase | |
| Török et al. | High-performance liquid chromatographic enantioseparation of bicalutamide and its related compounds | |
| CN104133029A (en) | Method for determining optical purity of solifenacin succinate intermediate | |
| Pyrgaki et al. | Stereoselective determination of the epimer mixtures of itraconazole in human blood plasma using HPLC and fluorescence detection | |
| Ghanty et al. | RP-HPLC method for estimation of valsartan in solid oral dosage forms | |
| Zongde et al. | Analytical and semipreparative resolution of enatiomers of albendazole sulfoxide by HPLC on amylose tris (3, 5-dimethylphenylcarbamate) chiral stationary phases | |
| Subasranjan et al. | An improved validated ultra high pressure liquid chromatography method for separation of tacrolimus impurities and its tautomers | |
| CN115469032B (en) | Method for measuring arginine perindopril Li Yigou body by high performance liquid chromatography |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171121 |